Representative Jonathan L. Jackson (Democratic-Illinois) recently bought shares of Guardant Health, Inc. (NASDAQ:GH). In a filing disclosed on October 19th, the Representative disclosed that they had bought between $15,001 and $50,000 in Guardant Health stock on September 28th. The trade occurred in the Representative’s “MORGAN STANLEY TRUST ACCOUNT” account.
Representative Jonathan L. Jackson also recently made the following trade(s):
- Purchased $50,001 – $100,000 in shares of Estee Lauder Companies (NYSE:EL) on 9/28/2026.
- Sold $50,001 – $100,000 in shares of Viasat (NASDAQ:VSAT) on 9/28/2026.
- Sold $50,001 – $100,000 in shares of Walmart (NASDAQ:WMT) on 9/28/2026.
- Purchased $50,001 – $100,000 in shares of Datadog (NASDAQ:DDOG) on 9/28/2026.
- Sold $1,001 – $15,000 in shares of Tortoise Energy Infrastructure (NYSE:TYG) on 9/4/2026.
- Sold $1,001 – $15,000 in shares of Viasat (NASDAQ:VSAT) on 8/28/2026.
Guardant Health Trading Up 3.0%
NASDAQ GH opened at $162.59 on Wednesday. Guardant Health, Inc. has a 12 month low of $66.59 and a 12 month high of $191.05. The stock has a 50 day moving average of $167.70 and a 200-day moving average of $140.50. The company has a market cap of $21.82 billion, a PE ratio of -46.59 and a beta of 1.58.
Guardant Health (NASDAQ:GH – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.34. The firm had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. During the same quarter in the prior year, the business earned ($0.44) EPS. The business’s revenue was up 44.3% compared to the same quarter last year. As a group, sell-side analysts predict that Guardant Health, Inc. will post -3.02 EPS for the current fiscal year.
Analyst Ratings Changes
A number of brokerages have weighed in on GH. Citigroup boosted their price target on Guardant Health from $150.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Rothschild & Co Redburn assumed coverage on Guardant Health in a research note on Tuesday, September 8th. They issued a “buy” rating and a $203.00 price target on the stock. Evercore reiterated an “outperform” rating and issued a $200.00 price objective on shares of Guardant Health in a report on Monday, July 6th. Barclays increased their price objective on shares of Guardant Health from $200.00 to $220.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Finally, Guggenheim upped their target price on Guardant Health from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $190.00.
Get Our Latest Research Report on Guardant Health
Insider Buying and Selling
In related news, CEO Amirali Talasaz sold 37,500 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $169.16, for a total value of $6,343,500.00. Following the transaction, the chief executive officer owned 37,500 shares in the company, valued at $6,343,500. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CTO Darya Chudova sold 7,738 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $178.00, for a total transaction of $1,377,364.00. Following the sale, the chief technology officer directly owned 70,635 shares in the company, valued at $12,573,030. This trade represents a 9.87% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 178,940 shares of company stock worth $30,070,911. Corporate insiders own 5.60% of the company’s stock.
Hedge Funds Weigh In On Guardant Health
Several hedge funds and other institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company bought a new stake in shares of Guardant Health during the second quarter worth $208,592,000. William Blair Investment Management LLC bought a new position in shares of Guardant Health in the 2nd quarter valued at $196,737,000. Orbimed Advisors LLC acquired a new position in Guardant Health in the 1st quarter worth about $40,199,000. Eagle Health Investments LP bought a new stake in Guardant Health during the 2nd quarter worth approximately $45,112,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Guardant Health in the 2nd quarter worth approximately $32,316,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.
About Representative Jackson
Jonathan Jackson (Democratic Party) is a member of the U.S. House, representing Illinois’ 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.
Jackson (Democratic Party) is running for re-election to the U.S. House to represent Illinois’ 1st Congressional District. He declared candidacy for the 2026 election.
Jonathan Jackson was born in Chicago, Illinois. Jackson graduated from Whitney Young High School. He earned an M.B.A. from Northwestern University. Jackson’s career experience includes working as an investment analyst and an entrepreneur.
Guardant Health Company Profile
Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.
The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.
Featured Stories
- Five stocks we like better than Guardant Health
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
